Ozempic & GLP-1 Lawsuit in Texas

GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, and Trulicity — were prescribed to millions of Texas residents for type 2 diabetes and weight management. While these drugs were marketed as breakthrough treatments, growing evidence has linked them to severe and sometimes permanent injuries that the manufacturers allegedly failed to adequately disclose.

The federal litigation against Novo Nordisk and Eli Lilly has been consolidated into multidistrict litigation (MDL 3094) in the Eastern District of Pennsylvania. Texas residents who suffered injuries from GLP-1 medications can file claims that join this consolidated proceeding, benefiting from coordinated pretrial discovery while retaining their individual right to trial.

The lawsuits allege that the manufacturers knew their drugs could cause serious gastrointestinal injuries — including stomach paralysis, bowel blockages, and pancreatic inflammation — as well as vision loss, yet they prioritized profits over patient safety by failing to warn prescribers and patients about the true scope of these risks. For Texas residents, the stakes are high: these injuries can be permanent, require multiple surgeries, and fundamentally alter quality of life.

As the litigation progresses, early bellwether trials are expected to set the stage for broader settlement discussions. Texas residents who have been injured should evaluate their claims now, before filing deadlines expire.

Texas legal landscape: Texas applies a modified comparative fault rule with a 51% bar. The state follows the learned intermediary doctrine, directing failure-to-warn claims toward the prescribing physician's knowledge, and caps punitive damages at the greater of two times economic damages plus $750,000 or $200,000. Residents in Houston, Dallas, San Antonio, Austin, and Fort Worth and surrounding areas should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claim.